Horizon Pharma to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2012 Financial Results on March 18,

Horizon Pharma to Host Conference Call and Webcast to Discuss Fourth Quarter 
and Full Year 2012 Financial Results on March 18, 2013 
DEERFIELD, IL -- (Marketwire) -- 03/04/13 --  Horizon Pharma, Inc.
(NASDAQ: HZNP) announced today that its fourth quarter and year ended
December 31, 2012 financial results will be released on Monday, March
18, 2013. Following the announcement, Horizon's management will host
a live conference call and webcast at 8:00 am Eastern Time to review
the Company's financial and operating results and provide a general
business update.  
The live webcast and a replay may be accessed by visiting Horizon's
website at http://ir.horizon-pharma.com. Please connect to the
Company's website at least 15 minutes prior to the live webcast to
ensure adequate time for any software download that may be needed to
access the webcast. Alternatively, please call 1-888-338-8373 (U.S.)
or 973-872-3000 (international) to listen to the conference call. The
conference ID number for the live call is 11959520. Telephone replay
will be available approximately two hours after the call. To access
the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406
(international). The conference ID number for the replay is 11959520. 
About Horizon Pharma
 Horizon Pharma, Inc. is a specialty
pharmaceutical company that has developed and is commercializing
DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic
needs in arthritis, pain and inflammatory diseases. The Company's
strategy is to develop, acquire, in-license and/or co-promote
additional innovative medicines where it can execute a targeted
commercial approach in specific therapeutic areas while taking
advantage of its commercial strengths and the infrastructure the
Company has put in place. For more information, please visit
www.horizonpharma.com. 
Contacts:
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
investor-relations@horizonpharma.com 
Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
kgalante@burnsmc.com